Hargreaves RH[au] - Search Results

Year	Number of Results
1995	1
1996	1
1997	1
1998	1
1999	2
2000	2
2001	1
2002	1
2005	1
2008	1
2011	1
2012	1
2019	1
2022	0

1

Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones.

Hargreaves RH, Hartley JA, Butler J. Hargreaves RH, et al. Front Biosci. 2000 Nov 1;5:E172-80. doi: 10.2741/hargreav. Front Biosci. 2000. PMID: 11056081 Review.

2

Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.

Wahking RA, Hargreaves RH, Lockwood SM, Haskell SK, Davis KW. Wahking RA, et al. Among authors: hargreaves rh. Ann Pharmacother. 2019 Aug;53(8):801-805. doi: 10.1177/1060028019835202. Epub 2019 Feb 27. Ann Pharmacother. 2019. PMID: 30813751

3

Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.

Ward TH, Danson S, McGown AT, Ranson M, Coe NA, Jayson GC, Cummings J, Hargreaves RH, Butler J. Ward TH, et al. Among authors: hargreaves rh. Clin Cancer Res. 2005 Apr 1;11(7):2695-701. doi: 10.1158/1078-0432.CCR-04-1751. Clin Cancer Res. 2005. PMID: 15814651 Free article.

4

The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol.

Zoethout RW, Iannone R, Bloem BR, Palcza J, Murphy G, Chodakewitz J, Buntinx A, Gottesdiener K, Marsilio S, Rosen L, van Dyck K, Louis ED, Cohen AF, Schoemaker RC, Tokita S, Sato N, Koblan KS, Hargreaves RH, Renger J, van Gerven JM. Zoethout RW, et al. Among authors: hargreaves rh. J Psychopharmacol. 2012 Feb;26(2):292-302. doi: 10.1177/0269881111398685. Epub 2011 Feb 18. J Psychopharmacol. 2012. PMID: 21335358 Clinical Trial.

5

Development of a lyophilised RH1 formulation: a novel DT diaphorase activated alkylating agent.

Elliott MA, Ford SJ, Walker AA, Hargreaves RH, Halbert GW. Elliott MA, et al. Among authors: hargreaves rh. J Pharm Pharmacol. 2002 Apr;54(4):487-92. doi: 10.1211/0022357021778754. J Pharm Pharmacol. 2002. PMID: 11999125

6

Discovery of quinolinediones exhibiting a heat shock response and angiogenesis inhibition.

Hargreaves RH, David CL, Whitesell LJ, Labarbera DV, Jamil A, Chapuis JC, Skibo EB. Hargreaves RH, et al. J Med Chem. 2008 Apr 24;51(8):2492-501. doi: 10.1021/jm7014099. Epub 2008 Mar 26. J Med Chem. 2008. PMID: 18363347

7

Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.

Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, Ross D. Winski SL, et al. Among authors: hargreaves rh. Biochem Pharmacol. 2001 Jun 15;61(12):1509-16. doi: 10.1016/s0006-2952(01)00631-1. Biochem Pharmacol. 2001. PMID: 11377380

8

A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.

Winski SL, Hargreaves RH, Butler J, Ross D. Winski SL, et al. Among authors: hargreaves rh. Clin Cancer Res. 1998 Dec;4(12):3083-8. Clin Cancer Res. 1998. PMID: 9865924

9

Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.

Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D. Beall HD, et al. Among authors: hargreaves rh. Mol Pharmacol. 1995 Sep;48(3):499-504. Mol Pharmacol. 1995. PMID: 7565631

10

The abnormal cytotoxicities of 2,5-diaziridinyl-1,4-benzoquinone-3-phenyl esters.

Di Francesco AM, Hargreaves RH, Wallace TW, Mayalarp SP, Hazrati A, Hartley JA, Butler J. Di Francesco AM, et al. Among authors: hargreaves rh. Anticancer Drug Des. 2000 Oct;15(5):347-59. Anticancer Drug Des. 2000. PMID: 11354311

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results